Phenotyping Diabetic Retinopathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00840541|
Recruitment Status : Completed
First Posted : February 10, 2009
Last Update Posted : April 7, 2014
|Condition or disease|
This study aims to validate and characterize phenotypes of diabetic retinopathy (DR) progression using ophthalmic and systemic data from type-2 diabetic subjects followed at the AIBILI Clinical Trial Center in the last 10 years.
Macular Edema (ME) development during the study period, mainly Clinically Significant ME (CSME) needing treatment, will be the primary indicator for DR progression. CSME will be considered as the primary end-point and will be used to identify phenotypes (and risk markers) of DR progression.
|Study Type :||Observational|
|Actual Enrollment :||80 participants|
|Official Title:||Observational Study of Type-2 Diabetic Subjects to Validate Diabetic Retinopathy Phenotypes|
|Study Start Date :||January 2009|
|Primary Completion Date :||January 2010|
|Study Completion Date :||January 2012|
Type-2 diabetic subjects diagnosed with diabetic retinopathy (DR).
- CSME [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00840541
|AIBILI - Clinical Trial Center|
|Coimbra, Portugal, 3000-548|
|Principal Investigator:||José Cunha-Vaz, MD PhD||Association for Innovation and Biomedical Research on Light and Image|